Tygacil Injection, Powder, Lyophilized, For Solution
Product Images NDC 0008-4990

G2 miectables are a pharmaceutical product distributed by Wyeth Pharmaceuticals, a subsidiary of Pfizer Inc, based in Philadelphia, PA 19101.*

This text appears to be a medication label for Tygacil (Tigecycline) injection solutions. It includes the National Drug Code (NDC) 0008-4990-19, which indicates that the solution should be prescribed by a healthcare provider. The solution comes in a single-dose vial that is yellow to orange in color, and any unused solution should be discarded. The package insert should be consulted for complete instructions on use. The solution contains 100 mg of lactose monohydrate and is adjusted with HCl and possibly NaOH. This medication is distributed by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. The label includes a lot number (8920288RB) for identification purposes.*

This is a pharmaceutical product description for a medication called Tygacil, manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. The medication is lyophilized powder that requires reconstitution before administration, and is used for intravenous infusion. The product is available in 50mg single-dose vials, and the recommended dosage is an initial dose of 100mg, followed by 50mg every 12 hours. The reconstituted solution should be further diluted for IV infusion, and the resultant solution should contain 10 mg/mL. The reconstituted solution should be yellow to orange in color; If not, the solution should be discarded. The product contains lactose monohydrate and the pH is adjusted with hydrochloric acid and, if necessary, sodium pyridoxine, but it does not contain any preservatives. Storage temperature ranges from 20°C to 25°C.*